About Synthena
Synthena is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its proprietary tricyclo-DNA technology platform offers broad advantages over state of the art oligonucleotide chemistries for new RNA intervention strategies like splice switching, and other antisense approaches. Its most advanced preclinical drug development program focuses on Duchenne Muscular Dystrophy, a genetic disorder which affects 1/3,500 boys and which leads to death in early adulthood.
Facts about Synthena
Facts about Synthena
- Focus : Manufacturer
- Industry : Biotechnology
Product portfolio of Synthena
Here you will find Synthena AG
Last viewed contents
Bischoff Analysentechnik und -geräte GmbH - Leonberg, Germany
Victorian Infectious Diseases Reference Laboratory - Victoria, Australia
Agilent Technologies to acquire Silicon Genetics, leading provider of life science informatics
Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha Antagonist - Study to examine safety and tolerability in solid tumors and lymphoma
Serotonin mediates exercise-induced generation of new neurons
